Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247061764> ?p ?o ?g. }
- W4247061764 endingPage "547" @default.
- W4247061764 startingPage "539" @default.
- W4247061764 abstract "Topiroxostat, an inhibitor of xanthine oxidoreductase (XOR) was shown to reduce urinary albumin excretion of hyperuricemic patients with chronic kidney disease. However, its pharmacological mechanism is not well understood. In this study, we examined the effects of topiroxostat on glomerular podocytes. Podocyte is characterized by foot process and a unique cell-cell junction slit diaphragm functioning as a final barrier to prevent proteinuria. The effects of topiroxostat on the expressions of podocyte functional molecules were analysed in db/db mice, a diabetic nephropathy model, anti-nephrin antibody-induced rat podocyte injury model and cultured podocytes treated with adriamycin. Topiroxostat treatment ameliorated albuminuria in db/db mice. The expression of desmin, a podocyte injury marker was increased, and nephrin and podocin, key molecules of slit diaphragm, and podoplanin, an essential molecule in maintaining foot process were downregulated in db/db mice. Topiroxostat treatment prevented the alterations in the expressions of these molecules in db/db mice. XOR activity in kidney was increased in rats with anti-nephrin antibody-induced podocyte injury. Topiroxostat treatment reduced XOR activity and restored the decreased expression of nephrin, podocin and podoplanin in the podocyte injury. Furthermore, topiroxostat enhanced the expression of podoplanin in injured human cultured podocytes. Podocyte injury was evident in db/db mice. Topiroxostat ameliorated albuminuria in diabetic nephropathy model by preventing podocyte injury. Increase of XOR activity in kidney contributes to development of podocyte injury caused by stimulation to slit diaphragm. Topiroxostat has an effect to stabilize slit diaphragm and foot processes by inhibiting the reduction of nephrin, podocin and podoplanin. El topiroxostat, un inhibidor de la xantina oxidorreductasa (XOR), mostró reducir la excreción de albúmina en la orina de pacientes hiperuricémicos con enfermedad renal crónica. Sin embargo, su mecanismo farmacológico no se conoce con exactitud. En este estudio examinamos los efectos del topiroxostat en los podocitos glomerulares. El podocito se caracteriza por unas prolongaciones en forma de pie y un diafragma de hendidura de unión célula-célula único que funciona como barrera final en la prevención de la proteinuria. Se analizaron los efectos del topiroxostat en las expresiones de las moléculas funcionales de los podocitos en ratones db/db, en un modelo de nefropatía diabética, en un modelo de lesión podocitaria inducida por anticuerpos antinefrina en ratas y en podocitos cultivados tratados con adriamicina. El tratamiento con topiroxostat mejoró la albuminuria en ratones db/db. La expresión de la desmina, un marcador de lesión podocitaria, estaba aumentada, y la nefrina y la podocina, moléculas clave del diafragma de hendidura, y la podoplanina, una molécula esencial en el mantenimiento de las prolongaciones en forma de pie, estaban atenuadas en los ratones db/db. El tratamiento con topiroxostat evitó alteraciones en las expresiones de estas moléculas en los ratones db/db. La actividad de la XOR en el riñón se incrementó en ratas con lesión podocitaria inducida por anticuerpos antinefrina. El tratamiento con topiroxostat redujo la actividad de la XOR y restauró la disminución de la expresión de nefrina, podocina y podoplanina en la lesión podocitaria. Además, el topiroxostat aumentó la expresión de podoplanina en podocitos humanos cultivados lesionados. La lesión podocitaria era evidente en ratones db/db. El topiroxostat mejoró la albuminuria en el modelo de nefropatía diabética al prevenir la lesión podocitaria. El aumento de la actividad de la XOR en el riñón contribuye al desarrollo de la lesión podocitaria causada por la estimulación del diafragma de hendidura. El topiroxostat tiene un efecto de estabilización del diafragma de hendidura y de las prolongaciones en forma de pie al inhibir la reducción de nefrina, podocina y podoplanina." @default.
- W4247061764 created "2022-05-12" @default.
- W4247061764 creator A5003754594 @default.
- W4247061764 creator A5006041066 @default.
- W4247061764 creator A5027562520 @default.
- W4247061764 creator A5042973046 @default.
- W4247061764 creator A5043241033 @default.
- W4247061764 creator A5052010897 @default.
- W4247061764 creator A5057301328 @default.
- W4247061764 date "2021-09-01" @default.
- W4247061764 modified "2023-10-16" @default.
- W4247061764 title "Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin" @default.
- W4247061764 cites W2005043762 @default.
- W4247061764 cites W2038619003 @default.
- W4247061764 cites W2040196961 @default.
- W4247061764 cites W2052675962 @default.
- W4247061764 cites W2056498299 @default.
- W4247061764 cites W2075930028 @default.
- W4247061764 cites W2089725385 @default.
- W4247061764 cites W2090874502 @default.
- W4247061764 cites W2097655320 @default.
- W4247061764 cites W2107724793 @default.
- W4247061764 cites W2111255580 @default.
- W4247061764 cites W2125113922 @default.
- W4247061764 cites W2129416468 @default.
- W4247061764 cites W2133691034 @default.
- W4247061764 cites W2139122702 @default.
- W4247061764 cites W2146378769 @default.
- W4247061764 cites W2165581077 @default.
- W4247061764 cites W2168450345 @default.
- W4247061764 cites W2317329941 @default.
- W4247061764 cites W2322876490 @default.
- W4247061764 cites W2761836300 @default.
- W4247061764 cites W2789891715 @default.
- W4247061764 cites W2794478750 @default.
- W4247061764 cites W2995682951 @default.
- W4247061764 cites W3005337864 @default.
- W4247061764 cites W4251743604 @default.
- W4247061764 doi "https://doi.org/10.1016/j.nefroe.2021.11.007" @default.
- W4247061764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36165136" @default.
- W4247061764 hasPublicationYear "2021" @default.
- W4247061764 type Work @default.
- W4247061764 citedByCount "1" @default.
- W4247061764 countsByYear W42470617642023 @default.
- W4247061764 crossrefType "journal-article" @default.
- W4247061764 hasAuthorship W4247061764A5003754594 @default.
- W4247061764 hasAuthorship W4247061764A5006041066 @default.
- W4247061764 hasAuthorship W4247061764A5027562520 @default.
- W4247061764 hasAuthorship W4247061764A5042973046 @default.
- W4247061764 hasAuthorship W4247061764A5043241033 @default.
- W4247061764 hasAuthorship W4247061764A5052010897 @default.
- W4247061764 hasAuthorship W4247061764A5057301328 @default.
- W4247061764 hasBestOaLocation W42470617641 @default.
- W4247061764 hasConcept C126322002 @default.
- W4247061764 hasConcept C134018914 @default.
- W4247061764 hasConcept C185592680 @default.
- W4247061764 hasConcept C2776174234 @default.
- W4247061764 hasConcept C2776855237 @default.
- W4247061764 hasConcept C2777146197 @default.
- W4247061764 hasConcept C2779561371 @default.
- W4247061764 hasConcept C2779922275 @default.
- W4247061764 hasConcept C2780091579 @default.
- W4247061764 hasConcept C2780819817 @default.
- W4247061764 hasConcept C3018201436 @default.
- W4247061764 hasConcept C71924100 @default.
- W4247061764 hasConcept C86803240 @default.
- W4247061764 hasConcept C95444343 @default.
- W4247061764 hasConceptScore W4247061764C126322002 @default.
- W4247061764 hasConceptScore W4247061764C134018914 @default.
- W4247061764 hasConceptScore W4247061764C185592680 @default.
- W4247061764 hasConceptScore W4247061764C2776174234 @default.
- W4247061764 hasConceptScore W4247061764C2776855237 @default.
- W4247061764 hasConceptScore W4247061764C2777146197 @default.
- W4247061764 hasConceptScore W4247061764C2779561371 @default.
- W4247061764 hasConceptScore W4247061764C2779922275 @default.
- W4247061764 hasConceptScore W4247061764C2780091579 @default.
- W4247061764 hasConceptScore W4247061764C2780819817 @default.
- W4247061764 hasConceptScore W4247061764C3018201436 @default.
- W4247061764 hasConceptScore W4247061764C71924100 @default.
- W4247061764 hasConceptScore W4247061764C86803240 @default.
- W4247061764 hasConceptScore W4247061764C95444343 @default.
- W4247061764 hasIssue "5" @default.
- W4247061764 hasLocation W42470617641 @default.
- W4247061764 hasLocation W42470617642 @default.
- W4247061764 hasOpenAccess W4247061764 @default.
- W4247061764 hasPrimaryLocation W42470617641 @default.
- W4247061764 hasRelatedWork W1527928972 @default.
- W4247061764 hasRelatedWork W2038108331 @default.
- W4247061764 hasRelatedWork W2040575932 @default.
- W4247061764 hasRelatedWork W2375069092 @default.
- W4247061764 hasRelatedWork W2387531317 @default.
- W4247061764 hasRelatedWork W2892179242 @default.
- W4247061764 hasRelatedWork W4247061764 @default.
- W4247061764 hasRelatedWork W4249900324 @default.
- W4247061764 hasRelatedWork W4285165033 @default.
- W4247061764 hasRelatedWork W50918418 @default.
- W4247061764 hasVolume "41" @default.
- W4247061764 isParatext "false" @default.